UK markets open in 6 hours 36 minutes

Biofrontera AG (BFRA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
5.20-0.09 (-1.70%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close5.29
Open5.33
Bid5.15 x 800
Ask5.35 x 3100
Day's range5.20 - 5.41
52-week range4.67 - 9.87
Volume3,604
Avg. volume7,317
Market cap152.498M
Beta (5Y monthly)1.53
PE ratio (TTM)N/A
EPS (TTM)-0.65
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.50
  • Globe Newswire

    Biofrontera reports preliminary approximate revenues for the month of September 2021

    Leverkusen, Germany, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of September 2021. The Company’s preliminary, unaudited revenue from product sales in September 2021 was in the range of EUR 2.3 and 2.5 million, compared to EUR 1.8 million in September 2020, an increase of about 33%. Preliminary revenues from product sales in t

  • Globe Newswire

    Biofrontera reports preliminary revenue for the month of August 2021

    Leverkusen, Germany, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of August 2021. The Company’s preliminary, unaudited revenue from product sales in August 2021 amounted to approximately EUR 1,485 thousand, compared to EUR 1,341 thousand in August 2020, an increase of 11%. Preliminary revenues from product sales in the US were

  • Globe Newswire

    Biofrontera reports financial results for the six months ended June 30, 2021

    Leverkusen, Germany, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the six months ended June 30, 2021. Key financial figures and business performance for the six months ended June 30, 2021 In EUR thousands6M 2021 6M 2020 ChangeRevenue13,09416,117-19% thereof from product sales13,0949,676+35%Gross profit on sales11,08214,625-24%Research and develop